Showing 441 - 460 results of 119,786 for search '(( 2 n decrease ) OR ( 5 ((((wt decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 2.02s Refine Results
  1. 441
  2. 442
  3. 443
  4. 444
  5. 445
  6. 446

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  7. 447
  8. 448
  9. 449

    GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

    Published 2021
    “…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”
  10. 450
  11. 451
  12. 452
  13. 453

    Brain and liver GCase activity are significantly decreased in heterozygous <i>GBA1</i> D409V KI mice, with varying differences in glucosphingolipid lipids in brain and liver. by Nicole K. Polinski (10947787)

    Published 2021
    “…<p>(A-B) GCase, (C-D) gluocosylceramide (GlcCer), and (E-F) glucosylsphingosine (GlcSph) levels measured in whole brain homogenate and liver homogenate of C57Bl/6 wild type (WT) and <i>GBA1</i> D409V KI heterozygous (HET) mice at 5 months of age (n = 10/age). …”
  14. 454
  15. 455
  16. 456
  17. 457
  18. 458
  19. 459
  20. 460

    NatB inactivation decreased the level of MAPK and proposed model of EGFR/MAPK signaling regulation by NatB and the N-end rule pathways. by Zhentao Sheng (107495)

    Published 2020
    “…Drk/Grb2 and MAPK, two positive components of the EGFR signaling pathway are targeted for degradation by the Arg/N-end rule pathway and E3 ubiquitin ligase Ubr4 while PP2AC, a negative regulator of EGFR signaling pathway, is targeted for degradation by the Ac/N-end rule pathway E3 ubiquitin ligase Cnot4. …”